CD274 and neoplasm: PD-L1 tumour expression was TC1 in 25.0%, TC2 in 18.3%, and TC3 in 56.7% of patients who underwent the atezolizumab plus carboplatin and nab-paclitaxel regimen versus TC1 in 18.8%, TC2 in 21.9%, and TC3 in 59.3% of patients who underwent the carboplatin and nab-paclitaxel regimen (p = 0.708).